These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 16206346

  • 1. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis JC.
    J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
    [Abstract] [Full Text] [Related]

  • 2. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.
    Zhonghua Yi Xue Za Zhi; 2006 Sep 19; 86(35):2451-4. PubMed ID: 17156669
    [Abstract] [Full Text] [Related]

  • 3. Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response.
    Kim TH, Stone M, Payne U, Zhang X, Ionescu M, Lobanok T, King L, Poole AR, Inman RD.
    Arthritis Rheum; 2005 Mar 19; 52(3):885-91. PubMed ID: 15751093
    [Abstract] [Full Text] [Related]

  • 4. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
    Woo JH, Lee HJ, Sung IH, Kim TH.
    J Rheumatol; 2007 Aug 19; 34(8):1753-9. PubMed ID: 17610317
    [Abstract] [Full Text] [Related]

  • 5. [Clinical study of etanercept for treating ankylosing spondylitis].
    Liang LQ, Zhan ZP, Ye YJ, Fu D, Xu HS, Yang XY.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug 19; 28(8):1349-51. PubMed ID: 18753057
    [Abstract] [Full Text] [Related]

  • 6. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.
    Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, Emery P, Poole AR, Veale DJ.
    Arthritis Rheum; 2003 Nov 19; 48(11):3085-95. PubMed ID: 14613270
    [Abstract] [Full Text] [Related]

  • 7. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2003 Jun 19; 48(6):1667-75. PubMed ID: 12794835
    [Abstract] [Full Text] [Related]

  • 8. Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis.
    Arends S, van der Veer E, Groen H, Houtman PM, Jansen TL, Leijsma MK, Bijzet J, Limburg PC, Kallenberg CG, Spoorenberg A, Brouwer E.
    J Rheumatol; 2011 Aug 19; 38(8):1644-50. PubMed ID: 21632677
    [Abstract] [Full Text] [Related]

  • 9. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.
    Arthritis Rheum; 2009 Nov 15; 61(11):1484-90. PubMed ID: 19877087
    [Abstract] [Full Text] [Related]

  • 10. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
    Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD.
    Arthritis Rheum; 2002 Jan 15; 46(1):21-30. PubMed ID: 11817593
    [Abstract] [Full Text] [Related]

  • 11. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC, Chung SJ, Park YB, Lee SK.
    Scand J Rheumatol; 2008 Jan 15; 37(3):173-8. PubMed ID: 18465450
    [Abstract] [Full Text] [Related]

  • 12. Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers.
    Cibere J, Thorne A, Kopec JA, Singer J, Canvin J, Robinson DB, Pope J, Hong P, Grant E, Lobanok T, Ionescu M, Poole AR, Esdaile JM.
    J Rheumatol; 2005 May 15; 32(5):896-902. PubMed ID: 15868627
    [Abstract] [Full Text] [Related]

  • 13. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T.
    Ann Rheum Dis; 2008 Mar 15; 67(3):353-7. PubMed ID: 17644538
    [Abstract] [Full Text] [Related]

  • 14. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, Liang TH, Liao HT, Tsai CY, Wei JC, Chou CT.
    Rheumatology (Oxford); 2006 Apr 15; 45(4):414-20. PubMed ID: 16287916
    [Abstract] [Full Text] [Related]

  • 15. Effects of etanercept on serum biochemical markers of cartilage metabolism in patients with spondyloarthropathy.
    Briot K, Roux C, Gossec L, Charni N, Kolta S, Dougados M, Garnero P.
    J Rheumatol; 2008 Feb 15; 35(2):310-4. PubMed ID: 18203315
    [Abstract] [Full Text] [Related]

  • 16. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, Gromnica-Ihle E, Franz J, Burmester GR, Jung K.
    J Rheumatol; 1999 Feb 15; 26(2):251-8. PubMed ID: 9972954
    [Abstract] [Full Text] [Related]

  • 17. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
    Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study Group.
    Arthritis Rheum; 2003 Nov 15; 48(11):3230-6. PubMed ID: 14613288
    [Abstract] [Full Text] [Related]

  • 18. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors.
    Pedersen SJ, Sørensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Lambert R, Hansen A, Østergaard M.
    Ann Rheum Dis; 2011 Aug 15; 70(8):1375-81. PubMed ID: 21551511
    [Abstract] [Full Text] [Related]

  • 19. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J.
    Rheumatology (Oxford); 2005 Mar 15; 44(3):342-8. PubMed ID: 15561737
    [Abstract] [Full Text] [Related]

  • 20. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
    Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmartí R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S.
    Ann Rheum Dis; 2004 Dec 15; 63(12):1594-600. PubMed ID: 15345498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.